The imaging community was not particularly interested in the past in helping the
pharmaceutical industry with imaging as biomarkers, because this is not our community's …

Over the past decade, biomarkers have been recognized as a critical element needed to
improve predictability and efficiency in the process of developing more effective, more …

The Critical Path Initiative (CPI) of the US Food and Drug Administration (FDA), initiated in
2004 and updated with a list of opportunities and guidelines, has 2 key premises:(1) imaging …

In 2011, new nuclear medicine residency program recommendations included an increased
emphasis on molecular imaging in clinical practice, and the American Board of Nuclear …

Discussion among summit participants in the Drug Discovery breakout session focused on
identifying challenges and promising strategies for meeting these challenges in the current …

During our Annual Meeting, SNM sent more than 150 members to Capitol Hill to talk to their
representatives about issues affecting molecular imaging and nuclear medicine. The topics …

The FDA, in particular, has written extensively of its vision of the future where imaging
agents of all types will play a pivotal role in speeding up drug development in early clinical …

Medicine includes a report of a promising agent for the radiopharmaceutical therapy of
metastatic melanoma (1). The report is provocative for several reasons: it provides a …

Radioactive imaging agents, like diagnostic drugs generally, undergo a drug development
process that parallels that of therapeutic agents, with similar development times but …

In response to this challenge, in September of this year SNM launched an innovative
process for integrating imaging biomarkers into phase 1, 2, and 3 clinical trials of new …